$8.68
+0.00 (+0.00%)
Last updated: Apr 16, 2026 00:50
Fundamentals Overview
Sage Therapeutics, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Risk (Beta)
0.3 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
Sentiment weakening (3 downgrades)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Recent institutional grades: majority downgrades. Current institutional positions: Hold: 11, Neutral: 10, Overweight: 2, Perform: 1, Sector Outperform: 2, Sector Perform: 2, Underperform: 2.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-6.63; current price is $8.68. That’s a -176.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 1.47 |
| P/S (TTM) | 9.31 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 9.16 |
| Quick Ratio (TTM) | 9.16 |
| Cash Ratio (TTM) | 1.51 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -3.55% |
| Gross margin (TTM) | 96.43% |
| Operating margin (TTM) | -3.82% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for SAGE.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Scotiabank | downgrade | Sector Outperform | Sector Perform | 2025-07-08 |
| Baird | maintain | Neutral | Neutral | 2025-06-20 |
| Truist Securities | maintain | Hold | Hold | 2025-06-17 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2025-06-17 |
| Piper Sandler | downgrade | Overweight | Neutral | 2025-06-17 |
| Canaccord Genuity | maintain | Hold | Hold | 2025-06-17 |
| Needham | maintain | Hold | Hold | 2025-06-16 |
| Needham | maintain | Hold | Hold | 2025-04-30 |
| Needham | maintain | Hold | Hold | 2025-04-25 |
| Scotiabank | maintain | Sector Outperform | Sector Outperform | 2025-02-12 |
| Canaccord Genuity | maintain | Hold | Hold | 2025-02-12 |
| Wedbush | maintain | Neutral | Neutral | 2025-02-12 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2025-02-12 |
| Needham | maintain | Hold | Hold | 2025-02-12 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-01-02 |
| Stifel | maintain | Hold | Hold | 2024-12-16 |
| TD Cowen | maintain | Hold | Hold | 2024-11-21 |
| RBC Capital | upgrade | Underperform | Sector Perform | 2024-11-21 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-11-20 |
| Piper Sandler | maintain | Overweight | Overweight | 2024-10-30 |
| Truist Securities | maintain | Hold | Hold | 2024-10-30 |
| Scotiabank | maintain | Sector Outperform | Sector Outperform | 2024-10-30 |
| Oppenheimer | maintain | Perform | Perform | 2024-10-30 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-10-30 |
| Baird | maintain | Neutral | Neutral | 2024-10-09 |
| B of A Securities | maintain | Underperform | Underperform | 2024-10-09 |
| HC Wainwright & Co. | maintain | Neutral | Neutral | 2024-10-09 |
| Wedbush | maintain | Neutral | Neutral | 2024-10-09 |
| RBC Capital | downgrade | Sector Perform | Underperform | 2024-10-04 |
| Truist Securities | maintain | Hold | Hold | 2024-08-14 |